INmune Bio (NASDAQ:INMB) Stock Price Down 0.2%

INmune Bio, Inc. (NASDAQ:INMB)’s share price traded down 0.2% on Tuesday . The stock traded as low as $10.94 and last traded at $11.18. 63,843 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 104,750 shares. The stock had previously closed at $11.20.

INmune Bio Price Performance

The firm has a market cap of $203.48 million, a PE ratio of -6.69 and a beta of 1.92. The business has a 50-day moving average price of $11.14 and a two-hundred day moving average price of $10.65.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.47) EPS for the quarter. INmune Bio had a negative net margin of 19,360.00% and a negative return on equity of 64.11%. The business had revenue of $0.03 million during the quarter.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently made changes to their positions in INMB. Financial Advocates Investment Management raised its stake in INmune Bio by 8.6% in the 4th quarter. Financial Advocates Investment Management now owns 12,500 shares of the company’s stock valued at $141,000 after purchasing an additional 990 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of INmune Bio during the third quarter valued at approximately $223,000. Fermata Advisors LLC lifted its stake in shares of INmune Bio by 6.9% during the first quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock valued at $370,000 after buying an additional 2,025 shares during the period. Finally, Janney Montgomery Scott LLC boosted its position in INmune Bio by 14.5% during the third quarter. Janney Montgomery Scott LLC now owns 256,887 shares of the company’s stock worth $1,739,000 after acquiring an additional 32,482 shares during the last quarter. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.